Skip to content

Comparison of TUSP Versus TURP for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume

Comparison of Transurethral Split of the Prostate Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume: A Prospective Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04912349
Enrollment
150
Registered
2021-06-03
Start date
2020-07-01
Completion date
2022-06-30
Last updated
2021-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Brief summary

Comparison of transurethral split of the prostate versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia in a small prostate volume: A prospective controlled study

Detailed description

Transurethral resection of the prostate (TURP) was considered as the golden standard to treat benign prostatic hyperplasia (BPH) for decades. However, TURP was associated with low efficiency to alleviate the lower urinary tract symptoms and a significantly higher risk of bladder neck contracture (BNC) for patients with small-volume BPH. We aimed to compare the therapeutic effect of transurethral split of the prostate (TUSP) with TURP for patients with small-volume BPH (\<30 ml). In this study, some selected small-volume BPH patients were randomly divided into two groups (TUSP and TURP group). The patient's baseline characteristics and perioperative outcomes were recorded. The follow-up was made at 6 months, 1 year and 2 years after surgical treatment.

Interventions

PROCEDURETUSP

Patients received the transurethral split of the prostate(TUSP) treatment.

PROCEDURETURP

Patients received the transurethral resection of the prostate(TURP) treatment.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
35 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Benign prostatic hyperplasia patients with surgical indication * Maximum flow rate \<12ml/s * Prostate volume \<30ml * The international prostate symptoms score\>21 * Medication of α-adrenergic blockers for at least 3 months

Exclusion criteria

* Acute prostatitis and urethritis * Neurogenic bladder * Abnormal prostate-specific antigen level * Urethral injury history

Design outcomes

Primary

MeasureTime frameDescription
international prostate symptoms score(IPSS)within 24 months after surgeryMeasuring the International Prostate Symptoms Score by a questionnaire (which minimum value is zero and the maximum value is 35; higher scores mean a worse outcome)
maximum urinary flow rate(Qmax)within 24 months after surgeryMeasuring the maximum urinary flow rate by a urodynamic study

Countries

China

Contacts

Primary ContactJiaming Wen, Dr.
wenjiaming@zju.edu.cn+86-571-87783550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026